Notícias e Atividades da Imbria Pharmaceuticals

Fusão, aquisição e financiamento envolvendo Imbria Pharmaceuticals.

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Imbria Pharmaceuticals

• Alvin Shih, Chief Executive Officer
• Charles Dunn, Director
• Ken Horne, Director

Recentes movimentos de executivos em Imbria Pharmaceuticals

• James Januzzi antes Director, agora é Senior Research Advisor  (Notícia publicada em 17 de setembro de 2025).
• Pavan Cheruvu, ingressou na Companhia como Independent Chairman of the Board  (Notícia publicada em 17 de setembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Imbria Pharmaceuticals.

Imbria Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Imbria Pharmaceuticals

• Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• View more press releases Close

Redes sociais sobre Imbria Pharmaceuticals

• Imbria Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Imbria Pharmaceuticals na LinkedIn, X (Twitter) e YouTube